{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.57","upperLimit":"89.17","value":"75.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"476"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"OG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population\n\nPharmacokinetic samples from 476 participants included in studies CC-4047-MM-005 and CC 4047 MM 010 were used for the population PK analysis of pomalidomide","reportingStatus":"POSTED","timeFrame":"Cycles 1, 2, 3, 4, 5, 6","title":"Pomalidomide Exposure - Apparent Volume of Distribution (V/F)","type":"SECONDARY","unitOfMeasure":"Liters"}